FMS Kinase Inhibitors: Current Status and Future Prospects
- FMS Kinase Inhibitors: Current Status and Future Prospects
- 모하메드엘가말; 하난; 유경호; 오창현
- FMS; CSF-1; CSF-1R; IL-34; monoclonal antibodies; FMS kinase inhibitors
- Issue Date
- Medicinal research reviews
- VOL 33, NO 3, 599-636
- FMS, first discovered as the oncogene responsible for FelineMcDonough Sarcoma, is a type
III receptor tyrosine kinase that binds to the macrophage or monocyte colony-stimulating factor (M-CSF or CSF-1). Signal transduction through that binding results in survival, proliferation, and differentiation of monocyte/macrophage lineage. Overexpression of CSF-1 and/or FMS has been implicated in a number of disease states such as the growth of metastasis of certain types of cancer, in promoting osteoclast proliferation in bone osteolysis, and many inflammatory disorders. Inhibition of CSF-1 and/or FMS may help treat these pathological conditions. This article reviews FMS gene, FMS kinase, CSF-1, IL-34, and their roles in bone osteolysis, cancer biology, and inflammation. Monoclonal antibodies, FMS crystal structure, and small molecule FMS kinase inhibitors of different chemical scaffolds are also reviewed.
- Appears in Collections:
- KIST Publication > ETC
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.